Over the last few years, there has been a rising demand for targeted therapies with high potency compounds such as high potency active pharmaceutical ingredients and certain cytotoxic drugs. Oncology appears to be the leading domain for these products and increased use in the treatment of certain cancer indications has gained much attention due to the low dosage requirements and lower side effects. Antibody-Drug Conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer. By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, ADC’s are able to discriminate between healthy and diseased tissue, in contrast to traditional chemotherapy agents which attack both. The ADC’s can target and attack the cancer cells so that healthy cells are less severely affected. With over 25% of drugs manufactured worldwide being classified as highly potent1, this market is currently cited as one of the most important segments of pharmaceutical industry.
To read more go to http://www.pharmpro.com/article/2014/08/trends-high-tox-manufacturing